CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| EA6141 | ECOG-ACRIN | Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| A051701 | Alliance | Randomized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double-Expressing Lymphomas | Adult CIRB - Late Phase Emphasis | Available to Open |
| RTOG-1216 | RTOG | Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk, Squamous Cell Cancer of the Head and Neck | Adult CIRB - Late Phase Emphasis | Available to Open |
| NRG-LU007 | NRG | RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial | Adult CIRB - Late Phase Emphasis | Available to Open |
| S2012 | SWOG | Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) | Adult CIRB - Late Phase Emphasis | Available to Open |
| E4599 | ECOG | Randomized Phase II/III Trial of Paclitaxel plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients with Advanced Nonsquamous NSCLC | Adult CIRB - Late Phase Emphasis | Completed |
| NRG-CC003 | NRG | Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with Or without Hippocampal Avoidance for Small Cell Lung Cancer | Cancer Prevention and Control CIRB | Available to Open |
| NRG-HN009 | NRG | Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Adult CIRB - Late Phase Emphasis | Available to Open |
| NRG-HN004 | NRG | Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin | Adult CIRB - Late Phase Emphasis | Available to Open |
| NRG-HN006 | NRG | Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |